AnaptysBio

Yahoo Finance • 15 days ago

Sector Update: Health Care Stocks Softer Late Afternoon

Health care stocks declined late Friday afternoon, with the NYSE Health Care Index down 0.8% and the PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 15 days ago

Sector Update: Health Care Stocks Retreat Friday Afternoon

Health care stocks declined Friday afternoon, with the NYSE Health Care Index down 0.6% and the Stat PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 15 days ago

Anaptys to spin-off First Tracks Biotherapeutics, announces $100M buyback

* AnaptysBio (ANAB [https://seekingalpha.com/symbol/ANAB]) has approved the spin-off of First Tracks Biotherapeutics, the company said on Friday. * The new company is expected to begin regular trading on the Nasdaq on April 20, 2026, u... Full story

Yahoo Finance • last month

AnaptysBio Details Plan to Split Into RoyaltyCo and Biopharma at TD Cowen Healthcare Conference

AnaptysBio logo Key Points AnaptysBio is moving forward with a near-term split into two public companies — a low-cost royalty company holding Jemperli and future imsidolimab royalties, and a development-focused biopharma company housing... Full story

Yahoo Finance • 2 months ago

Anaptys Announces Participation at Upcoming Investor Conferences

SAN DIEGO, Feb. 05, 2026 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executiv... Full story

Yahoo Finance • 2 months ago

Biotech Leader Eyes Spinoff Amid Massive Sales Surge

Biotech stock Anaptysbio cleared a trendline entry near 50 on Monday. Shares are also in a base with a buy point of 52.47. Continue Reading... Full story

Yahoo Finance • 4 months ago

J.P. Morgan Maintains a Sell Rating on GSK plc (GSK)

GSK plc (NYSE:GSK) is one of the best pharma stocks to invest in. J.P. Morgan analyst Richard Vosser maintained a Sell rating on GSK plc (NYSE:GSK) on December 8, setting a price target of £17.00.Is GSK plc (GSK) the Best Undervalued UK St... Full story

Yahoo Finance • 4 months ago

Quality stocks present “once in a generation” opportunity – top stocks as per SA Quant

[Businessman showing the upward arrow on the chart. Technology innovation on a virtual screen. Concept of development and growth business efficiency, and increase productivity] leolintang/iStock via Getty Images Investors facing historica... Full story

Yahoo Finance • 4 months ago

SA Quant ranks Goldman's small-cap stocks with largest short interest

[Multi screen fintech investing gold and silver trading on digital screen corporating with AI artificial intelligence financial business data on commodity investment] primeimages Goldman Sachs analysts last week identified 50 small-cap st... Full story

Yahoo Finance • 5 months ago

Anaptys Announces Participation in December Investor Conferences

SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executiv... Full story

Yahoo Finance • 5 months ago

Stocks making the biggest moves midday: Oracle, Bath & Body Works, Gap and more

Check out the companies making the biggest moves midday: Oracle — The AI stock fell 4% as investors remained worried about valuations tied to AI continued to dump stocks. Those declines added to Oracle's and Nvidia's steep weekly losses. B... Full story

Yahoo Finance • 5 months ago

AnaptysBio drops as litigation with GSK unit risks cancer therapy deal

Evelyn Mccarthy/E+ via Getty Images AnaptysBio (ANAB [https://seekingalpha.com/symbol/ANAB]) shares lost ~11% in the premarket on Friday after the U.S. drugmaker and its partner Tesaro, a subsidiary of GSK (GSK [https://seekingalpha.com/s... Full story

Yahoo Finance • 5 months ago

AnaptysBio sets $100M stock repurchase plan

* AnaptysBio (ANAB [https://seekingalpha.com/symbol/ANAB]) board has authorized an amended stock repurchase plan to buy back up to $100.0 million of its outstanding common stock. * This amendment is in addition to the $6.4 million that... Full story

Yahoo Finance • 5 months ago

Anaptys Announces $100 Million Stock Repurchase Plan

SAN DIEGO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that its Board of Directors has authorized an... Full story

Yahoo Finance • 5 months ago

TESARO Pursues Litigation Against AnaptysBio For Alleged Material Breach Of Jemperli Agreement

(RTTNews) - GSK plc.'s (GSK) subsidiary TESARO Inc. has commenced litigation against AnaptysBio Inc. (ANAB), contending that AnaptysBio has materially violated the terms of their licensing agreement related to the oncology drug Jemperli.... Full story

Yahoo Finance • 5 months ago

Anaptys Initiates Litigation Against Tesaro, a GSK Subsidiary

SAN DIEGO, Nov. 21, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, announced it has filed a Verified Complaint in Delaware Chance... Full story

Yahoo Finance • 5 months ago

GSK's Tesaro Sues AnaptysBio Over Jemperli License Dispute

(RTTNews) - GSK plc (GSK), a biopharmaceutical company's subsidiary Tesaro, Inc. (TSRO), on Friday announced that it has filed litigation in the Delaware Chancery Court against AnaptysBio, Inc. (ANAB), alleging a material breach of their l... Full story

Yahoo Finance • 5 months ago

Anaptys Announces Participation in November Investor Conferences

SAN DIEGO, Nov. 04, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executiv... Full story

Yahoo Finance • 5 months ago

Anaptys Announces Third Quarter 2025 Financial Results and Provides Business Update

Announced intent to separate biopharma operations from substantial royalty assets by YE 2026Phase 2 top-line data through Week 12 for rosnilimab, a pathogenic T cell depleter, in ulcerative colitis on track for Nov./Dec. 2025Phase 2b data... Full story

Yahoo Finance • 5 months ago

Anaptys Announces New Positive Phase 2b Trial Results for Rosnilimab in Rheumatoid Arthritis at ACR Late-Breaking Oral Presentation

New data reinforce rosnilimab’s efficacy profile in rheumatoid arthritis (RA) with deepening of clinical responses, including CDAI remission, from Week 12 to Week 28 regardless of prior advanced therapy, including JAKsNew data confirm dura... Full story